ENVIRONMENTAL SCIENCE AND ENGINEERING
Https://jese.online
Editor@jese.online
ISSN : 3104-4026 (Print)
ISSN : 3104-4034 (Online)
Journal of Environmental Science and Engineering

THE ROLE OF BIOPRINTING IN PERSONALIZED MEDICINE: ENGINEERING 3D PRINTED DRUG DELIVERY SYSTEMS FOR CUSTOMIZED THERAPEUTICS

Article History

Received:
January 15, 2024

Revised:
February 09, 2024

Accepted:
March 23, 2024

Available Online:
June 30, 2024

Nida Hafeez [1*], **Saad Abdullah**[2]

[1]Department of Computer Science, Bahria University Lahore

[2]Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan

*Corresponding Author E-mail: nidah.bulc@bahria.edu.pk

Abstract

This study explores the potential of 3D printed drug delivery systems (DDS) in personalized medicine, focusing on the development and evaluation of customized therapeutics. The primary aim was to engineer bioprinted DDS capable of sustained drug release, improved bioactivity, and enhanced mechanical stability. The results demonstrated a controlled drug release over 72 hours, significantly improving therapeutic effectiveness compared to traditional drug delivery methods, which typically show rapid drug release followed by suboptimal effects. Bioactivity assays revealed a notable increase in cell viability, with the 3D printed DDS exhibiting a 95.6% cell viability rate, compared to 75.3% for traditional systems. Mechanical integrity testing confirmed that the 3D printed DDS maintained structural stability under compression, with a maximum stress at deformation of 3.5 MPa, outperforming traditional DDS. Tests on the synthesized drug delivery system indicated its high biocompatible nature by demonstrating low levels of toxicity in cytotoxicity measurements. The technical evaluations confirmed that 3D-printed DDS released medication at higher levels compared to standard versions and maintained excellent compatibility with biological networks alongside strong material strength thus establishing itself as a promising medicine customization platform. Studies indicate how 3D printed DDS system enables patient-customer tailored release methods resulting in enhanced drug control programs. This technology requires additional technical developments in suitable biomaterials along with improved clinical application scale to effectively use. The main research priority in future 3D bioprinting studies must include improvements to technology along with its clinical practicality.

Keywords: “3D Printing”, “Drug Delivery Systems”, “Personalized Medicine”, “Bioactivity”, “Mechanical Integrity”, “Biocompatibility”.

INTRODUCTION

The fusion of biotechnology with 3D printing technology has led to bioprinting becoming an important developing field that provides personalized medical treatments which researchers now actively study. The development of unique healthcare solutions through biologic measurements of patient specifics stands as the main goal of personified medical services. Through bioprinting strategies medical researchers can develop individualized drug delivery systems that enhance therapeutic effectiveness and minimize adverse reactions while producing better patient results since this technique constructs biological tissues in layered formation (Shah et al., 2023). 3D printed drug delivery systems (DDS) by Smith et al. (2022) present a solution to typical drug delivery limitations like low bioavailability combined with restricted drug release control and impaired accuracy of target area delivery.

Scientists achieve multiple-scale drug delivery systems by building APIs into biomimetic materials with human tissue structures along with biotolerance to the body through bioprinting methods. Scientists use dosage customization capabilities to design DDS systems with precise attributes for individual patient needs and superior treatment results and controlled drug release rates per Muller et al. (2021). Through sustained release the precise delivery rates of drugs across extended time spans can be managed by medical employees due to the beneficial drug delivery system of 3D printed DDS (Lee et al., 2023).

The field of modern medicine now concentrates on developing DDS through bioprinting specific to individual patients while adding functional elements that fulfill all medical criteria. Research has enabled the creation of intricate patterns for physiological matching using three bioprinting techniques which include extrusion-printing while incorporating inkjet-printing and laser-harmonized printing (Zhang et al., 2022). Such structures can provide targeted body region treatments by using distinct cells combined with both pharmaceuticals and growth hormones (Park et al., 2023).

Better pharmaceutical profiles in drug delivery systems have become achievable through new bioprinting developments. Traditional drug delivery systems use systemic distribution as their method but this practice often generates unexpected drug levels with undesirable side effects. Bioprinted DDS enables specific drug delivery to decrease side effects and remove the requirement for excessive medication doses according to Singh et al. (2023). Targeted medication delivery through this approach represents a highly beneficial strategy for cancer treatment since it enhances therapeutic benefits and decreases systemic toxicity (Kim et al., 2021).

Through uniting tissue engineering and 3D bioprinting the creation of drug delivery systems becomes possible which allows drugs to interact better with human tissues (Vasquez et al., 2022). Researchers can produce tissues by bioprinting that match the blood-brain barrier properties based on the research by Chang et al (2024) to develop DDS for diseases where this protective barrier restricts the therapeutic response such as Alzheimer's disease. The benefits of conventional implantable drug delivery techniques become possible through bioprinted vascularized tissues which enable medical professionals to develop DDS positioned inside the human body for sustained drug release (Zhao et al., 2021).

The main obstacles remain to be tackled before achieving successful customized treatment through the use of 3D printed Drug Delivery Systems. Sustainable development of suitable biomaterials presenting vital cellular support with controlled strength properties and drug release regulation remains a substantial barrier (Jiang et al., 2021). The main impediment for introducing bioprinted DDS into medical practice is sustaining the system's ability to scale up production and replicate results (Xie et al., 2023). Bioprinted drug delivery systems need specific regulatory frameworks for assuring both their new technology and patient-specific nature and their security and effectiveness. The frameworks show potential complexity according to Tian et al. (2022).

Specific treatment delivery through bioprinting encounters challenges yet experts agree that this method represents a strong potential solution. Bioprinted drug delivery system development will transform these tools into essential components for creating patient-tailored therapeutic interventions. The main emphasis of this study investigates customized medicine's usage of drug delivery systems printed in three dimensions through engineering-based approaches. The exploration of existing bioprinting technologies and biomaterial development and drug delivery advances allows for achieving improved health outcomes in individual patients.

RESEARCH METHODS

The research methodology explores DDS engineering for personalized treatment through 3D printed delivery systems and analyzes bioprinting applications in personalized medicine. A thorough examination of published literature starts the research method to expose contemporary techniques regarding 3D bio-printing along with drug delivery systems and bioprinting methods and personalized medicine. The initial phase leads to selecting materials along with printing methods that enable the creation of specialized DDS operations. The manufacturing process of drug delivery systems involves experimental evaluation of three different 3D bioprinting techniques after completing technology identification and material selection steps. The selected 3D printing methods consist of extrusion-based printing and inkjet printing and laser-assisted printing. Medical staff create drug-containing structures through techniques that combine biocompatible polymers with APIs while following precise arrangements to recreate human body environments. In vitro evaluations of mechanical properties along with drug release behavior take place after printing in order to assess a DDS. Simulated body fluids (SBF) serve as human body mimics to determine how controlled medication release happens throughout extended durations. The evaluation of manufactured printed systems for biocompatibility and cytotoxicity happens under test conditions that involve cell cultures once DDS manufacturing stability and functional aspects are validated. The evaluation checks the active state and cellular growth behavior while examining cell-validated relationships between DDS elements. The primary objective of this method is to create DDS systems which meet essential patient-specific drug administration criteria while advancing Towards the use of printed DDS in personalized treatments. The DDS performance is evaluated through comparison of in vitro experimental findings against drug delivery technology methods and statistical studies quantify both the system viability and the bioprinted DDS's efficiency. The Figure 1 illustration demonstrates the important steps of design, printing and assessment found in the methodology flowchart. The flowchart demonstrates how the research proceeds step by step through literature research

followed by experimental manufacture and evaluation. The flowchart establishes research transparency along with reproducibility through its visual depiction of the entire method.



Figure 1: Methodological flowchart outlining the sequential phases of the research process in developing 3D printed drug delivery systems.

This research about personalized drug delivery systems requires the implementation of the methodology diagrammed above. This research adopts a stepwise approach which connects multiple stages starting from literature review and technology discovery and material selection and moving to bioprinting and concluding with DDS testing. The direct flowcharts make research results both transparent to reviewers and easily replicable by other scientists.

RESULTS

This portion contains the research results regarding the development alongside evaluation of 3D printed drug delivery systems (DDS) used for making customized medicines. The main experimental findings regarding drug release profiles together with bioactivity tests and biocompatibility assessments and comparison with existing DDS technologies appear in multiple arranged tables and figures. The images showcase the data visually to show bioprinted system performances but the tables provide complete data sets that relate to fabrication and testing processes.

During a 72-hour period Table 1 presents the drug release data from the 3D printed DDS. The DDS provided controlled medication delivery in opposition to regular drug administration methods

that display initial rapid drug release followed by reduced medication effectiveness.

Table 1: Drug Release Profile of 3D Printed DDS

Time (hrs)	Drug Concentration (mg/ml)	Cumulative Release (%)
0	0.0	0.0
12	2.5	20.0
24	4.8	40.0
36	6.3	52.5
48	7.1	58.0
60	8.2	68.5
72	9.1	75.0

The bioactivity testing results from Table 2 demonstrate how the 3D printed DDS facilitates cell proliferation as well as enables cell-targeted interactions. The validity of bioprinted systems exceeded traditional drug delivery methods because they produced better cell viability results.

Table 2: Bioactivity of 3D Printed DDS (Cell Viability Test)

Drug Delivery System	Cell Viability (%)	Control Group (%)	p-value
3D Printed DDS	95.6	80.2	0.02
Traditional DDS	75.3	80.2	0.1

The mechanical resistance of bioprinted DDS exists within Table 3. Testing on the DDS through compression revealed that its structures could sustain pressure adequately for lasting in vivo application.

Table 3: Mechanical Integrity of 3D Printed DDS (Compression Test)

Sample	Maximum Compression (N)	Deformation (%)	Stress at Deformation (MPa)
DDS 1	150	10	3.2
DDS 2	140	12	2.9
DDS 3	160	8	3.5

Table 4 presents results about the cytotoxicity levels affecting the bioprinted DDS. The fabrication materials in the DDS demonstrate in vitro biocompatibility because they produce no significant cytotoxic effects which ensures their safety for clinical use.

Table 4: Cytotoxicity of 3D Printed DDS (MTT Assay)

Material	Cell Viability (%)	Control Group (%)	p-value
DDS 1	97.3	100	0.05
DDS 2	94.8	100	0.08
DDS 3	95.6	100	0.07

Table 5 compares the performance of the 3D printed DDS with conventional drug delivery systems. The 3D printed DDS achieved superior drug release benefits alongside improved bioactivity and greater mechanical resilience which unveils its potential use in personalized medicine.

Table 5: Comparison of 3D Printed DDS with Traditional DDS

Property	3D Printed DDS	Traditional DDS	p-value
Drug Release (hrs)	72	24	0.01
Cell Viability (%)	95.6	75.3	0.02
Compression Strength (MPa)	3.5	2.5	0.03



Figure 2: Drug release profile of the 3D printed DDS, showing sustained release over 72 hours.

The drug release profile of 3D printed DDS presents sustained and controlled drug release spanning 72 hours as depicted in Figure 2. Prolonged therapeutic effects result from the data showing the progressive drug release pattern.



Figure 3: Bioactivity comparison, demonstrating improved cell viability with the 3D printed DDS.

The figure depicts cell survival rates between 3D printed DDS and conventional drug delivery approaches. Assessment data indicates that the 3D printed DDS leads to higher cell viability numbers which demonstrate improved clinical potential.



Figure 4: Mechanical integrity of the 3D printed DDS, withstanding compression and maintaining stability.

The mechanical stability of the 3D printed DDS under stress can be evaluated through Figure 4's compression test data. Data shows that the DDS maintains its structural integrity under high pressures thus providing a reliable device for use.



Figure 5: Cytotoxicity test showing minimal effects, confirming biocompatibility of the 3D printed DDS.

Figure 5: Cytotoxicity test results for 3D printed DDS, showing minimal cytotoxic effects. The biocompatibility of the DDS suggests its safety for in vivo applications.



Figure 6: Performance comparison, highlighting superior drug release and mechanical properties of the 3D printed DDS.

Figure 6: Performance comparison between the 3D printed DDS and traditional drug delivery systems, highlighting the advantages of the bioprinted DDS in terms of drug release, bioactivity, and mechanical integrity.

DISCUSSION

Research findings show that drug delivery systems built through 3D printing exhibit excellent potential for individually designed medical therapies. Smith et al. (2022) established 3D printed DDS via bioprinting methods that released medication in a controlled manner for an extended duration per the findings. Drug release from this investigation showed an essential profile that stretched over time. Traditional drug delivery medical systems release their drugs prematurely causing problems with both rectification and negative adverse reactions per Lee et al. (2023). The 72-hour drug release duration validated previous research findings about 3D printed DDS becoming the promising technology for delivering reliable therapeutic outcomes.

Bioactivity together with mechanical strength and biocompatibility proved superior in the 3D printed DDS compared to traditional DDS. Chelberg Brown and their co-workers (2021) reinforced the advantages of 3D printed DDS by demonstrating increased cell survival and stable mechanical properties according to their data. The analysis by Brown indicated that 3D printed systems presented better structural stability since the DDS maintained its shape during compression tests. The outcomes of our cytotoxicity tests revealed minimal damaging consequences matching the results from Johnson et al. (2022) about bioprinted systems possessing superior biocompatibility when compared to conventional methods. Such an advanced and efficient drug delivery platform functions as an advanced option to traditional drug delivery systems for customized medical applications.

CONCLUSIONS

Medical science shows that 3D-printed medication delivery systems promise excellent opportunities for creating personalized healthcare solutions. Smith et al. (2022) developed 3D printed DDS via bioprinting to provide sustained drug release during an extended timeframe according to our research. The examined drug release profile showed necessary drug levels across all times. Typical drug delivery-based medical systems show fast drug depletion that leads to therapeutic disorders and adverse patient reactions (Lee et al., 2023). The 72-hour drug release duration of 3D printed DDS guarantees dependable therapeutic effectiveness according to our research which confirms earlier findings.

The bioactivity along with mechanical strength and optimized biocompatibility emerged as superior characteristics of the 3D printed DDS as compared to traditional DDS. Chelberg Brown and colleagues (2021) reported their findings which proved that 3D printed DDS improved both cell survival rates and maintained mechanical stability as well as other benefits. The 3D printed systems attained better structural stability after compression testing because the DDS maintained its physical form according to Brown's research findings. The cytotoxicity tests indicated low harmful effects on tissues which matches findings from Johnson et al.'s (2022) study about bioprinted systems and their higher biocompatibility compared to conventional methods. Such a cutting-edge and efficient drug delivery platform functions as a superior replacement for basic drug delivery systems in specialized medical applications.

REFERENCES

Chang, X., Zheng, Y., & Li, Y. (2024). 3D bioprinting for targeted drug delivery systems. Biomaterials, 52, 112-128.

Jiang, L., Wang, R., & Sun, J. (2021). Challenges in biomaterials for drug delivery systems: A review. Materials Science and Engineering C, 118, 111435.

Kim, H., Lee, J., & Lee, J. H. (2021). Bioprinting of drug delivery systems for cancer therapy. International Journal of Pharmaceutics, 594(1), 125584.

Lee, K., Hong, S., & Park, Y. (2023). 3D-printed drug delivery systems: A comprehensive review. Journal of Controlled Release, 338, 274-290.

Muller, R., Gebauer, J., & Herrmann, R. (2021). Novel drug delivery systems for personalized medicine. Advanced Drug Delivery Reviews, 177, 131-146.

Park, H., Kim, Y., & Lee, J. (2023). Personalized drug delivery using 3D bioprinting. Journal of Biomedicine and Biotechnology, 2023, 9171234.

Shah, P., Kumar, A., & Agarwal, M. (2023). 3D printing technologies in personalized drug delivery. Biotechnology Advances, 47, 107708.

Singh, G., Soni, R., & Kumar, S. (2023). 3D-printed drug delivery systems for personalized medicine. Pharmaceutical Research, 40(4), 450-464.

Smith, B., Wilson, H., & Green, D. (2022). Engineering of 3D printed drug delivery systems. Materials Today Communications, 27, 101658.

Tian, Z., Zhou, X., & Wang, L. (2022). Regulatory challenges in 3D bioprinting for personalized drug delivery. Regulatory Affairs Journal, 18(3), 88-95.

Vasquez, M., Silva, A., & Lin, J. (2022). Bioprinting for drug delivery systems: Challenges and advances. Journal of Drug Delivery Science and Technology, 67, 102863.

Xie, J., Zhao, C., & Zhang, Y. (2023). Advances in 3D bioprinting for drug delivery systems. Biomaterials Science, 11(3), 739-755.

Zhao, L., Ma, Y., & Liu, S. (2021). Vascularized bioprinted drug delivery systems: A step forward in personalized medicine. Bioengineering, 8(4), 42.

Zhang, H., Chen, L., & Zhang, J. (2022). Advances in bioprinting technologies for drug delivery. Biofabrication, 14(1), 011003.